Stock BDTX BLACK DIAMOND THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Black Diamond Therapeutics, Inc. OTC Markets

Equities

BDTX

US09203E1055

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Black Diamond Therapeutics, Inc. -.--% -.--%
16/05 HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating MT
09/05 Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Black Diamond Therapeutics, Inc. Announces Board and Committee Changes
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board
Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Black Diamond Therapeutics, Inc. Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
Black Diamond Therapeutics, Inc. Announces Management Changes
Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes
Black Diamond Therapeutics, Inc. Doses First Patients in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
BB Biotech dimezza la perdita trimestrale e dice addio a Piazza Affari
Sector Update: Health Care Stocks Steady Premarket Monday
Black Diamond Therapeutics Discloses Institutional Shareholder Equity Stake Expansion; Shares Jump Premarket
Black Diamond Therapeutics Prices $75 Million Common Stock Offering
Top Premarket Decliners
Black Diamond Therapeutics Launches $75 Million Stock Offering; Shares Drop After-Hours
Insider Sell: Black Diamond Therapeutics
Sector Update: Health Care Stocks Softer Late Tuesday
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BDTX Stock
  4. BDTX Stock
  5. News Black Diamond Therapeutics, Inc.
  6. Other languages